Adding Bevacizumab Has No Impact on Quality of Life in Glioblastoma
the Cancer Therapy Advisor take:
Adding bevacizumab to standard-of-care treatment of newly diagnosed glioblastoma during a progression-free period may have no impact on health-related quality of life, according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Martin Taphoorn, MD, PhD, of the Medical Center Haaglanden in the Netherlands examined patients who completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires C30 and BN20 upon each tumor assessment. They converted raw scores to a 100-point scale and evaluated mean changes from baseline scores.
The researchers found that mean changes from baseline did not reach clinically relevant differences in observed patients compared to placebo. Adding bevacizumab to radiotherapy with temozolomide (RT/TMZ) resulted in statistically longer deterioration-free survival across all health-related quality of life items.
Time to deterioration was also found to not be statistically longer in the placebo plus RT/TMZ group.
“The addition of bevacizumab to standard-of-care treatment for newly diagnosed glioblastoma had no impact on health-related quality of life during the progression-free period,” the authors concluded.
Adding bevacizumab to standard treatment of glioblastoma may have no impact on health-related quality of life.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer